Compare Gold Fields Limited (GFI) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Eli Lilly And Co — how do they compare? Gold Fields Limited trades at $32.32 (market cap $29.07B), while Eli Lilly And Co trades at $1,171.82 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 35.4× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (7.03%). Which is the better fit depends on your goals.
| GFI | LLY | |
|---|---|---|
Market Cap | $29.07B | $1.03T |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $1.24K |
52-Week Low | $23.95 | $625.65 |
Enterprise Value | $30.51B | $1.07T |
Dividend Yield | 7.03% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $33.33, down 0.6% with a bearish technical signal despite strong fundamental metrics including a P/E of 8.37, net income margin of 40.76%, and ROE of 52.33%. Recent earnings show mixed results with a Q1 2025 beat but subsequent misses. The company demonstrates robust cash flow growth with 2025 operating cash flow projected at $3.8B, while technical indicators show oversold conditions with RSI at 26.87.
GFI presents a compelling value opportunity with attractive valuation multiples and exceptional profitability metrics, though recent earnings misses and bearish technical momentum create near-term uncertainty. The 57% upside to the $52.75 consensus price target suggests significant potential, but investors should monitor operational execution and gold price volatility as key risk factors.
LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.
Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
